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ment may be more effective in reducing schizophrenia-related use
of inpatient services.
PMH25
A COMPARISON OF THE COST-EFFECTIVENESS OF
OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN
SELECTED NON-OECD COUNTRIES
Davey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M
M-TAG Pty Ltd, Chatswood, NSW, Australia
OBJECTIVES: To assess the cost-effectiveness of olanzapine
compared with other antipsychotics in the treatment of schizo-
phrenia in sixteen countries (Algeria, Croatia, Czech Republic,
Hungary, Israel, Latvia, Lithuania, Poland, Romania, Russia,
Saudi Arabia, Slovakia, Slovenia, South Africa, Turkey, and
United Arab Emirates). METHODS: Resource use data from
numerous double-blind randomised controlled trials of olanzap-
ine versus either risperidone or haloperidol were used to deter-
mine treatment costs. Resources considered were study drug,
concomitant medication and hospitalisations. Data relating to
lost production from unemployment and suicide were sourced
from literature. The trials also reported relative safety and efﬁ-
cacy. The doses used were those speciﬁed by the World Health
Organisation. Local prices and costs were applied to resource
utilisation from trials to estimate the overall direct costs associ-
ated with each therapy. Indirect costs were estimated using
average wages and labour data from national statistics ofﬁces.
RESULTS: This analysis, though retrospective, found Olanzi-
pine to be cost-effective or cost saving against haloperidol and
risperidone in all countries considered. The incremental total
cost of olanzapine over risperidone ranged from US$1232
(Israel) to US$470 (Algeria). Against haloperidol, the incremen-
tal total cost ranged from US$2353 (Israel) to US$996
(Romania). Cost-savings were largely driven by reduced hospi-
talisations. In terms of efﬁcacy, meta-analyses showed that com-
pared with risperidone, 10% more olanzapine patients achieved
a ≥40% PANSS improvement; 15% fewer required anticholin-
ergic medication and 12% fewer patients dropped out. Com-
pared to haloperidol these ﬁgures were 8%, 37% and 13%
respectively. These results indicate that olanzapine dominated
risperidone in Czech Republic, Lithuania and Slovakia; and
dominated both risperidone and haloperidol in Croatia,
Hungary, Israel, Saudi Arabia, Slovenia, South Africa and United
Arab Emirates. Olanzapine continued to be cost-effective in sen-
sitivity analyses. CONCLUSIONS: Olanzapine displays greater
efﬁcacy and is cost-effective or cost saving compared with
risperidone and haloperidol in the sixteen countries where analy-
ses were undertaken.
PMH26
OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF
DEPRESSION IN THE ELDERLY: A 5-YEAR POPULATION-
BASED STUDY
Dalal M, Pickard AS, Lin SJ
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVE: To determine if total out-of-pocket prescrip-
tion drug (OOPPD) expenditures by the community dwelling
elderly differ according to longitudinal patterns depression.
METHODS: Secondary data analyses were performed using the
population-based study of Assets and Health Dynamics
(AHEAD) of the Oldest Old (adults ≥ 65 years). Depression was
considered present if 4 or more depressive symptoms were
reported on the modiﬁed Center for Epidemiological Studies-
Depression Scale (CES-D). Three survey waves in 1995, 1998
and 2000 allowed depression to be characterized as persistent,
emergent, remittent, and recurrent. ANOVA and regression tech-
niques were used to estimate association between mean total
monthly OOPPD expenditures in 2000 based on depression
pattern. RESULTS: Of the 7027 elderly residents interviewed in
1995, 19% were lost to follow-up at 2000. More than 50% of
respondents never experienced signiﬁcant depressive symptoms.
Mean (SD) OOPPD expenditures for each pattern of depression
were: $221(1203) for recurrent (n = 63); $106(598) for emer-
gent (n = 324); $86(227) for remittent (n = 210); $78(138) for
persistent (n = 179); and $70($168) for never depressed (n =
3290). Only those with recurrent depression had signiﬁcantly
higher OOPPD expenditures compared to those without depres-
sion (ANOVA, p < 0.05). After adjusting for age, gender, and
comorbidity, recurrent and emergent patterns of depression were
associated with signiﬁcantly higher mean monthly OOPPD
expenditures compared to those without depression, while per-
sistent and remittent depression were not. CONCLUSIONS: The
community dwelling elderly with ﬂuctuating patterns of depres-
sion appear to pay more in monthly OOPPD expenditures than
the elderly with stable patterns, including chronic depression.
Upon testing of the robustness of the results using non-para-
metric and longitudinal random-effects models, further investi-
gation into the burden of illness based on longitudinal patterns
of depression is recommended.
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OBJECTIVE: This study provides a proﬁle over time of the incre-
mental health care costs of patients treated for depressive disor-
ders, including attention to medical treatment costs, drug
treatment costs, and incremental treatment costs (i.e., excess
costs as compared to controls) for coexistent medical and psy-
chiatric conditions. METHODS: Administrative claims data
from seven large U.S. companies were used to identify 3464
depressive disorder patients. A random sample of individuals
who were not treated for depressive disorders served as controls.
Incremental cost estimates were generated using a Tobit regres-
sion model including controls for age, gender, health plan, geo-
graphic location, and a number of medical conditions that tend
to precede the onset of depressive disorders. RESULTS: We esti-
mate that treated depressive disorder sufferers incur approxi-
mately $608 per month in incremental health care costs during
their ﬁrst depressive disorder episode. Of this total, 29.4 percent
are due to medical treatment costs, 6.2 percent are due to drug
treatment costs, and 64.4 percent are due to the incremental
treatment costs of coexisting conditions. The costs of treating
subsequent depressive disorder episodes decline. In addition,
while the incremental costs of treating other medical and psy-
chiatric conditions increase in the months prior to the ﬁrst
depression episode, these costs decrease in the months after a
ﬁnal depression episode. CONCLUSION: The health care costs
incurred by treated depressive disorder sufferers in the U.S. are
substantial. Depressive disorder patients experience a “run up”
of costs prior to an episode diagnosis and a subsequent “run
down” in costs after treatment for the condition. Future research
will investigate the indirect costs (i.e., work loss and work
cutback) associated with depressive disorders, as well as the
family burden of depressive episodes using the same time proﬁle
approach developed here.
